Jill Marie Broadfoot - Feb 3, 2025 Form 4 Insider Report for aTYR PHARMA INC (ATYR)

Role
Chief Financial Officer
Signature
/s/ Nancy E. Denyes, attorney-in-fact
Stock symbol
ATYR
Transactions as of
Feb 3, 2025
Transactions value $
-$4,740
Form type
4
Date filed
2/4/2025, 06:14 PM
Previous filing
Jan 10, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATYR Common Stock Options Exercise +3.75K +12.81% 33K Feb 3, 2025 Direct F1, F2, F3
transaction ATYR Common Stock Sale -$4.74K -1.25K -3.8% $3.78 31.8K Feb 4, 2025 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATYR Restricted Stock Unit Options Exercise $0 -3.75K -50% $0.00 3.75K Feb 3, 2025 Common Stock 3.75K Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Includes 1,307 shares acquired on November 15, 2024 under the Company's 2015 Employee Purchase Plan.
F4 Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
F5 The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.